TEL AVIV, Israel, Feb. 17, 2016 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Alcobra Ltd. (Nasdaq:ADHD), please be advised that the 2015 Cash and cash equivalents number in the Consolidated Balance Sheet Data should be $16,658, not $6,658 as originally reported. The complete corrected text follows:
Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced financial results for the three and twelve months ended December 31, 2015, and provided a corporate update.
